Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Life Sciences





Pravin Anand and Vaishali Mittal of Anand & Anand explain how they helped Swiss pharma company Vifor secure a landmark win against generic companies in India
Principals Martina Hufnal and Todd Garcia will lead the firm’s new life sciences industry group, which is set to 'formalise' certain practices
US pharma lawyers spoke to Managing IP about their top concerns and reveal how external counsel can help
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The UPC’s Court of Appeal said Mathys & Squire and Bristows hadn’t proved a 'direct and present interest' in Ocado v Autostore
The latest copy of a draft pandemic treaty shows the US and its allies are digging in over developing countries’ request for mandatory tech transfer
The latest working draft, seen by Managing IP, features competing visions of a pandemic IP regime advanced by the US and developing nations
The EPO declined to attend the latest meeting organised by the Industry Patent Quality Charter, a group that has called on the office to grant higher-quality patents
The Munich local division was wrong to side with Amgen over the drugmaker’s failure to upload annexes to its infringement suit on time, the appeal court ruled
Judge Matthias Zigann said the panel wasn’t convinced that NanoString had infringed the 10x Genomics patent
The Ministry of Health has passed a resolution declaring public interest in the drug dolutegravir
Johnson & Johnson won’t enforce patents for bedaquiline after months of public scrutiny and new licences for generics
Sponsored

Sponsored

The Biden administration has published draft guidance that could let the government override exclusive patent licences where drug prices are deemed too high
Mike Renaud, head of the IP division at Mintz, explains his business strategy and how the firm justifies charging higher rates
Counsel could be more hesitant to recommend means-plus-function claims for life sciences patents if the Federal Circuit rules against Xencor
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Interviews; Exclusives

Interviews; Exclusives

Fatima Hassan, director of Health Justice Initiative, says IP office actions can yield major wins for patients and activists
Each week Managing IP speaks to a different IP lawyer about their life and career
Counsel explain how they helped Eli Lilly overturn a damages award related to its migraine drug and why Supreme Court guidance proved useful
Samantak Ghosh, senior IP counsel at Gilead, talks about his pivot from research to law, the rise of biologics, and his pro bono work
Each week Managing IP speaks to a different IP lawyer about their life and career
Each week Managing IP speaks to a different IP lawyer about their life and career
In the latest episode of our monthly podcast, the team discusses AI clarifications from India and the US, and previews the upcoming Managing IP Awards for EMEA and the Americas
Managing IP’s Max Walters appeared on the latest episode of ‘Two IPs in a pod’, a regular podcast hosted by the UK patent attorney body, to discuss AI, awards and more
In the latest episode of our monthly podcast, the team discusses standard-essential patent developments so far this year and delves into law firm hiring strategies
In the final episode of 2023, the team discusses our Top 50 and the biggest IP events of the year
In the latest episode of our monthly podcast, the team discusses six months of India’s reformed system for foreign law firms, the latest UPC trends and SEP developments
In this special podcast, Managing IP talks to a charity that is working tirelessly to support mental health initiatives in the IP profession
In the latest episode of our monthly podcast, the team discusses law firm merger strategies, a high-profile break-up, and the latest 5G patent developments
In the latest episode of our monthly podcast, the team discusses their early memories of covering IP before delving into the latest on the UPC and whether a proposed US study could threaten the future of pharma patents
In the latest episode of our monthly podcast, the team discusses US and Asian approaches to the UPC, updates to trademark law in Japan and China, and the latest attempt at US patent reform
In the latest episode of our monthly podcast, the team joins you live from the Managing IP Intellectual Property & Innovation Summit in London, where SEPs and the UPC were both top of mind
ad ros bottom lb